Valuation: Precision Therapeutics Inc

Market Cap 104M 92.92M 85.72M 77.58M 145M 9.88B 147M 1.02B 408M 5.17B 389M 381M 16.38B P/E 2026 *
-5.04x
P/E 2027 * -79.7x
Enterprise Value 104M 92.92M 85.72M 77.58M 145M 9.88B 147M 1.02B 408M 5.17B 389M 381M 16.38B EV / Sales 2026 *
1.72x
EV / Sales 2027 * 0.24x
Free-Float
93.93%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Precision Therapeutics Inc

Manager TitleAgeSince
Chief Executive Officer 57 2026-02-08
Director of Finance/CFO - 2026-04-15
President - 2026-03-31
Director TitleAgeSince
Director/Board Member 66 2020-02-18
Chairman 78 2026-02-08
Director/Board Member 60 2020-07-08
Change 5-day change 1-year change 3-year change Capi.($)
-7.56%-8.33% - - 104M
+0.34%-3.03%+37.45%+61.06% 64.14B
+0.98%+2.26%+12.91%+82.98% 55.53B
+1.75%+2.76%+12.38%+103.69% 53.03B
-1.43%-0.57%+26.10%+52.86% 45.99B
-0.48%-3.86%+17.27%+117.99% 42.45B
+0.82%-2.06%+227.09%+922.41% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+44.58%+102.84%+88.74% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average -1.06%+3.82%+52.16%+163.25% 43.62B
Weighted average by Cap. -0.08%+3.13%+49.26%+160.88%

Financials

2026 *2027 *
Net sales 60.4M 54.1M 49.91M 45.17M 84.46M 5.75B 85.82M 595M 238M 3.01B 227M 222M 9.53B 431M 386M 356M 323M 603M 41.07B 613M 4.25B 1.7B 21.49B 1.62B 1.58B 68.08B
Net income -41.4M -37.08M -34.21M -30.96M -57.89M -3.94B -58.83M -408M -163M -2.06B -155M -152M -6.53B -4.5M -4.03M -3.72M -3.37M -6.29M -429M -6.39M -44.36M -17.7M -224M -16.89M -16.53M -710M
Net Debt - -
Logo Precision Therapeutics Inc
Axe Compute Inc. is a virtual neocloud AI infrastructure platform. The Company provides customers with access to graphics processing unit (GPU) compute capacity for artificial intelligence (AI) and other high-performance computing workloads through a distributed network model, including infrastructure made available through the Aethir network. It also operates a digital asset treasury focused on the Aethir token (ATH), the native utility token of the Aethir network. Its segments include Compute Services and Treasury Management and Drug Discovery Services. Its Drug Discovery Services segment provides services that include the application of AI using its proprietary biobank of tumor samples, as well as creation of proprietary 3D culture models used in drug development. The Company provides enterprises and AI innovators with flexibility across hardware, geography, and deployment models through two offerings: Axe Compute Access and Axe Compute Build.
Employees
-